Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,086,143 papers from all fields of science
Search
Sign In
Create Free Account
DT(388)IL3 fusion protein
Known as:
IL3R-targeting Fusion Protein SL-401
, SL-401
, DT(388)-IL3 Fusion Protein
Expand
A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
4 relations
NCIt Antineoplastic Agent Terminology
Peptide Elongation Factor 2
Positive Regulation of Apoptosis
Translational Repression
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm.
A. Lane
Hematology/Oncology Clinics of North America
2020
Corpus ID: 216218348
2019
2019
Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.
N. Pemmaraju
,
H. Ali
,
+17 authors
M. Patnaik
Journal of Clinical Oncology
2019
Corpus ID: 216626561
7058 Background: Patients with myelofibrosis (MF) who fail or are intolerant to JAK inhibitors (JAKi) have no standard treatment…
Expand
Review
2019
Review
2019
Treatment advances in blastic plasmacytoid dendritic cell neoplasm.
N. Pemmaraju
Clinical advances in hematology & oncology : H&O
2019
Corpus ID: 189816928
NP BPDCN is an aggressive cancer of the blood and bone marrow that presents clinically as a hybrid of lymphoma and leukemia. In…
Expand
2016
2016
Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.
N. Pemmaraju
,
A. Lane
,
+12 authors
M. Konopleva
2016
Corpus ID: 79346047
7006Background: SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed on BPDCN and…
Expand
2016
2016
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
M. Htut
,
C. Gasparetto
,
+9 authors
Claudia E. Paba-Prada
2016
Corpus ID: 79053767
Background: The bone marrow microenvironment of many multiple myeloma (MM) patients harbors high quantities of plasmacytoid…
Expand
Review
2015
Review
2015
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
E. Pelosi
,
G. Castelli
,
U. Testa
Blood Cells, Molecules & Diseases
2015
Corpus ID: 44691201
2015
2015
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid…
K. Sweet
,
N. Pemmaraju
,
+13 authors
M. Konopleva
2015
Corpus ID: 59190599
Background: SL-401 is a novel biologic delivering a truncated diphtheria toxin, a highly potent protein synthesis inhibitor, to…
Expand
2013
2013
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic…
A. Frankel
,
J. Woo
,
+13 authors
E. Rowinsky
2013
Corpus ID: 74318696
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematologic malignancy derived from plasmacytoid dendritic…
Expand
2012
2012
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML
M. Konopleva
,
D. Hogge
,
+15 authors
A. Frankel
2012
Corpus ID: 78116087
Abstract 3625 Background: SL-401 is a novel biologic targeted therapy, comprised of human IL-3 coupled to a truncated diphtheria…
Expand
2010
2010
Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and…
M. Konopleva
,
D. Hogge
,
+18 authors
A. Frankel
2010
Corpus ID: 78522692
Abstract 3298 Background and Rationale: SL-401 (DT388IL3) is a novel cancer stem cell (CSC)-directed recombinant biologic agent…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE